活体肾供者候选人的评估与咨询
本文综述了活体肾供者候选人评估与咨询领域的新进展。2021年eGFR种族中立公式、基因检测应用、2025年北美高血压诊断阈值降至≥130/80 mm Hg以及男性供者睾丸相关并发症风险新证据,均影响供者评估与咨询实践,政策制定者与移植项目需考虑这些发现对本地实践的影响。
要点
- 2021年eGFR种族中立公式可能使更多黑人候选者被排除在活体肾捐献之外。
- 对非洲裔活体肾供者可提供载脂蛋白L1基因分型,但其对供者资格的影响仍在研究中。
- 2025年北美指南将高血压诊断治疗阈值从≥140/90修订为≥130/80 mm Hg,影响供者评估。
核心结论
- 新研究改变了活体肾供者候选人评估与咨询的格局,涉及eGFR评估、基因检测、血压阈值和男性供者并发症风险。
研究设计与样本
- 综述文章,基于2017年KDIGO活体肾供者评估与照护临床实践指南及新研究进行汇总。
主要发现
- 2021年eGFR种族中立公式旨在促进健康公平,但单独依赖该指标可能使更多黑人候选者被排除在活体肾捐献之外。
- 生物学相关供者肾衰竭风险更高的证据积累,推动对家族性单基因肾病进行针对性评估。
- 2025年北美指南将高血压诊断和治疗阈值从≥140/90修订为≥130/80 mm Hg。
- 新证据支持男性供者候选人捐献后睾丸相关并发症风险高于非供者。
关键数值与推荐
- 2017年KDIGO指南为移植项目提供供者捐献前、中、后评估与照护建议。
- 2021年采用种族中立eGFR公式评估肾功能。
- 建议对非洲裔活体肾供者提供载脂蛋白L1基因分型。
- 2025年北美指南高血压诊断治疗阈值为≥130/80 mm Hg。
临床怎么用
- 移植项目应结合新证据更新供者评估与咨询流程,包括eGFR公式选择、基因检测指征和血压管理目标。
- 对非洲裔候选者提供载脂蛋白L1基因分型咨询,并告知结果对供者资格的不确定性。
- 对男性供者候选人告知捐献后睾丸相关并发症风险升高。
局限性
- 载脂蛋白L1结果对供者资格的影响仍在研究和辩论中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The evaluation of living kidney donor candidates is a complicated process to determine eligibility for donation and ensure that candidates are well-informed of postdonation risks, along with any uncertainty in risk estimations. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors provided recommendations to assist transplant programs in the evaluation and care of donors before, during, and after donation. In this review, we highlight new research that has changed the landscape of the evaluation and counseling of donor candidates. In 2021, a race-neutral equation for eGFR aimed to promote health equity; however, relying solely on this measure to assess kidney function may lead to more Black candidates being excluded from living kidney donation. The role of genetic testing in the evaluation of donor candidates continues to evolve as evidence accumulates about the higher risk of kidney failure among biologically related donors. Recent recommendations emphasize targeted evaluation for familial monogenic kidney diseases and suggest offering apolipoprotein L1 genotyping to living kidney donors of African ancestry, although the implications of apolipoprotein L1 results for donor eligibility is an area of ongoing research and debate. In 2025, North American guidelines revised the BP threshold for diagnosing and treating hypertension from ≥140/90 to ≥130/80 mm Hg. This will have implications in the assessment of donor candidates, who may be more likely to be declined for donation or put on hold until these new BP targets are reached. Finally, new evidence supports that male donor candidates should be informed of the higher risk of testicular-related complications postdonation compared with nondonors. Policy makers, guidance workgroups, and transplant programs will need to consider how these findings influence local practices related to the evaluation, counseling, and care of donor candidates.
引用
- Lam NN, Caliskan Y, Husain SA, et al. Evaluation and Counseling of Living Kidney Donor Candidates. J Am Soc Nephrol. 2026. PMID: 41805749. doi:10.1681/ASN.0000001082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。